Jacc: Cardiooncology最新文献

Cancer Survivors and Cardiovascular Risk: What Patients Should Know From the Perspective of Another Survivor 癌症幸存者与心血管风险：从另一位幸存者的角度看患者应知之事

IF 12 1区医学

Jacc: Cardiooncology Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.08.002

引用次数: 0

Full Issue PDF 全期 PDF

IF 12 1区医学

Jacc: Cardiooncology Pub Date : 2024-10-01 DOI: 10.1016/S2666-0873(24)00315-6

引用次数: 0

Cardiovascular Considerations Before Cancer Therapy 癌症治疗前的心血管注意事项

IF 12 1区医学

Jacc: Cardiooncology Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.07.017

引用次数: 0

Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction 癌症治疗相关心功能障碍改善患者停用心脏保护疗法后的预后情况

IF 12 1区医学

Jacc: Cardiooncology Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.07.018

{"title":"Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction","authors":"","doi":"10.1016/j.jaccao.2024.07.018","DOIUrl":"10.1016/j.jaccao.2024.07.018","url":null,"abstract":"<div><h3>Background</h3><div>The long-term prognosis after the discontinuation of cardioprotective therapy (CPT) in patients with cancer therapeutics–related cardiac dysfunction (CTRCD) that has shown improvement remains unclear.</div></div><div><h3>Objectives</h3><div>This study aims to assess the prognosis after CPT withdrawal in patients exhibiting improved CTRCD.</div></div><div><h3>Methods</h3><div>In this retrospective analysis of a single-center prospective cohort study, patients with improved CTRCD, defined as an increase in left ventricular ejection fraction (LVEF) ≥10 percentage points from the time of CTRCD diagnosis, were included. We analyzed their clinical outcomes, which included hospitalization for heart failure or a decrease in LVEF ≥10 percentage points within 2 years after CTRCD improvement, alongside echocardiographic changes.</div></div><div><h3>Results</h3><div>The cohort comprised 134 patients with improved CTRCD. The median follow-up duration after CTRCD diagnosis was 368.3 days (Q1-Q3: 160-536 days). After improvement, 90 patients continued CPT (continued group [CG]) and 44 withdrew CPT (withdrawn group [WG]). Among patients whose baseline LVEF at CTRCD diagnosis ranged from 45% to 55%, the final mean LVEF was comparable between both groups (CG: 64.9% ± 4.4% vs WG: 62.9% ± 4.2%; <em>P</em> = 0.059). However, for patients with a baseline LVEF <45%, the final mean LVEF was significantly lower in the WG (CG: 53.3% ± 6.4% vs WG: 48.2% ± 6.9%; <em>P</em> < 0.001). The occurrence of composite major clinical events was notably higher in the WG (HR: 3.06; 95% CI: 1.51-7.73; <em>P</em> = 0.002).</div></div><div><h3>Conclusions</h3><div>Patients who withdrew CPT after demonstrating improvement in CTRCD experienced worse clinical outcomes. Notably, a significant decrease in LVEF was observed after CPT withdrawal in patients with a baseline LVEF <45%.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes 前列腺癌男性患者的脂肪含量和肌肉力量与心血管预后

IF 12 1区医学

Jacc: Cardiooncology Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.07.011

{"title":"Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes","authors":"","doi":"10.1016/j.jaccao.2024.07.011","DOIUrl":"10.1016/j.jaccao.2024.07.011","url":null,"abstract":"<div><h3>Background</h3><div>There are limited data on the physical effects of androgen deprivation therapy (ADT) for prostate cancer (PC), and on the relationships of such measures of adiposity and strength to cardiovascular outcomes.</div></div><div><h3>Objectives</h3><div>The primary objective of this study was to evaluate the relationships of measures of adiposity and strength to cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, heart failure, arterial revascularization, peripheral arterial disease, and venous thromboembolism) in patients with PC. A secondary objective was to characterize the relationships between ADT use and 12-month changes in these physical measures.</div></div><div><h3>Methods</h3><div>This international, prospective cohort study included 3,967 patients with PC diagnosed in the prior 12 months or being treated with ADT for the first time. Median follow-up duration was 2.3 years.</div></div><div><h3>Results</h3><div>Participants’ mean age was 68.5 years, and 1,731 (43.6%) were exposed to ADT. ADT was associated with a 1.6% increase in weight, a 2.2% increase in waist circumference, a 1.6% increase in hip circumference, a 0.1% increase in waist-to-hip ratio, a 27.4% reduction in handgrip strength, and a 0.1% decrease in gait speed. High waist circumference and low handgrip strength were associated with adverse cardiovascular outcomes. Adjusting for age, education, race, tobacco and alcohol use, physical activity, cardiovascular disease, glomerular filtration rate, and ADT use, waist circumference above the highest quartile (110 cm) and handgrip strength below the lowest quartile (29.5 kg) were associated with higher likelihoods of a future cardiovascular event, with respective HRs of 1.40 (95% CI: 1.03-1.90; <em>P</em> = 0.029) and 1.59 (95% CI: 1.14-2.22; <em>P</em> = 0.006).</div></div><div><h3>Conclusions</h3><div>ADT was associated with increased adiposity and reduced strength over 12-month follow-up. High waist circumference and low baseline strength were associated with future adverse cardiovascular outcomes.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Carvedilol to Improve Cardiac Remodeling in Anthracycline-Exposed Childhood Cancer Survivors 卡维地洛改善受蒽环类药物影响的儿童癌症幸存者的心脏重塑状况

IF 12 1区医学

Jacc: Cardiooncology Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.07.015

引用次数: 0

Priorities in Cardio-Oncology 心脏肿瘤学的优先事项

IF 12 1区医学

Jacc: Cardiooncology Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.09.002

引用次数: 0

Guiding Treatment With Recovered CTRCD 指导已康复的 CTRCD 治疗

IF 12 1区医学

Jacc: Cardiooncology Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.09.003

引用次数: 0

Epigenomics of Cardio-Oncology 心脏肿瘤表观基因组学

IF 12 1区医学

Jacc: Cardiooncology Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.07.013

引用次数: 0

Use of Polygenic Risk Score for Prediction of Heart Failure in Cancer Survivors 利用多基因风险评分预测癌症幸存者的心力衰竭

IF 12 1区医学

Jacc: Cardiooncology Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.04.010

{"title":"Use of Polygenic Risk Score for Prediction of Heart Failure in Cancer Survivors","authors":"","doi":"10.1016/j.jaccao.2024.04.010","DOIUrl":"10.1016/j.jaccao.2024.04.010","url":null,"abstract":"<div><h3>Background</h3><div>The risk for heart failure (HF) is increased among cancer survivors, but predicting individual HF risk is difficult. Polygenic risk scores (PRS) for HF prediction summarize the combined effects of multiple genetic variants specific to the individual.</div></div><div><h3>Objectives</h3><div>The aim of this study was to compare clinical HF prediction models with PRS in both cancer and noncancer populations.</div></div><div><h3>Methods</h3><div>Cancer and HF diagnoses were identified using International Classification of Diseases-10th Revision codes. HF risk was calculated using the ARIC (Atherosclerosis Risk in Communities) HF score (ARIC-HF). The PRS for HF (PRS-HF) was calculated according to the Global Biobank Meta-analysis Initiative. The predictive performance of the ARIC-HF and PRS-HF was compared using the area under the curve (AUC) in both cancer and noncancer populations.</div></div><div><h3>Results</h3><div>After excluding 2,644 participants with HF prior to consent, 440,813 participants without cancer (mean age 57 years, 53% women) and 43,720 cancer survivors (mean age 60 years, 65% women) were identified at baseline. Both the ARIC-HF and PRS-HF were significant predictors of incident HF after adjustment for chronic kidney disease, overall health rating, and total cholesterol. The PRS-HF performed poorly in predicting HF among cancer (AUC: 0.552; 95% CI: 0.539-0.564) and noncancer (AUC: 0.561; 95% CI: 0.556-0.566) populations. However, the ARIC-HF predicted incident HF in the noncancer population (AUC: 0.804; 95% CI: 0.800-0.808) and provided acceptable performance among cancer survivors (AUC: 0.748; 95% CI: 0.737-0.758).</div></div><div><h3>Conclusions</h3><div>The prediction of HF on the basis of conventional risk factors using the ARIC-HF score is superior compared to the PRS, in cancer survivors, and especially among the noncancer population.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0